Jianbin Li

Jul 23, 2024 | onlinelibrary.wiley.com | Jianbin Li |Ding Zhang |Lida Tan |Chao-Jun Li

Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Jul 23, 2024 | onlinelibrary.wiley.com | Jianbin Li |Ding Zhang |Lida Tan |Longgang District Shenzhen

Conflict of Interests The authors declare no conflict of interest. Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Nov 4, 2023 | acsjournals.onlinelibrary.wiley.com | Jianbin Li |Zefei Jiang

INTRODUCTION Targeted therapy has become a crucial strategy for the treatment of patients with breast cancer. Improving the ability to recognize tumor cells with specific antigens and increasing tumor-killing activation and effectiveness have become major goals in drug discovery. Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against tumor cells.